1. Pink Sheet
  2. >>Market Access
  3. >>Government Payers
  4. >>Medicare

As Medicare Drug Negotiation Patient Sessions Kick Off, Advocates Already Eyeing Improvements

 
• By Sarah Karlin-Smith

Patient advocates see IRA patient listening sessions as an opening to push CMS to have more conversations on access issues in general, but first they want to work on improving the current process.

microphone at front of meeting room
reeMedicare will kick off 10 days of patient listening sessions on 30 October to inform its first round of drug price negotiations. • Source: Shutterstock

Patient advocacy groups are excited for Medicare’s upcoming listening sessions that will offer patients a chance to provide the Center for Medicare and Medicaid Services insight into the first slate of drugs subject to US government price negotiations while acknowledging that this initial foray into patient engagement with CMS is not ideal and that they are looking for ways to improve the process in the future.

Medicare will kick off 10 days of listening sessions on 30 October. Each 90-minute session will afford 20 speakers three minutes to provide insight on their day-to-day experience with conditions...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Medicare

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

More from Government Payers

New Guidance Suggests SubQ Keytruda, Opdivo Formulations May Not Avoid Medicare Negotiations

 
• By Sarah Karlin-Smith

New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.

House Budget Bill Includes Delayed Orphan Fix, Also Risks Downstream Cell and Gene Coverage

 
• By Sarah Karlin-Smith

The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.

Trump’s Rx Pricing Order: The Best-Case And Worst-Case Scenarios

 
• By Derrick Gingery

US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.